**Abstract**

**Objective:** Currently there are several compounds that are used in preclinical studies to target systems or receptors which are fundamental for consolidation and reconsolidation. While this offers an important opportunity to target these emotional memories and the expression of fear, and there is some validation from clinical studies, there is currently a need for roadmap that will assist in identification and evaluation of these compounds in their efficacy in treatment for PTSD. (This work is part of the Traumatic Stress Network of the European College of Neuropsychopharmacology).

**Method:** Two windows of opportunity that can be defined as \'golden hours\' for treatment of PTSD can be identified: i) event-based golden hours and ii) exposure-based golden hours. The first are defined by the traumatic event, and subsequent consolidation of the traumatic event. The second is determined by the setting in which exposure as a therapeutic tool is introduced and the subsequent reconsolidation phase.

**Summary:** First we will provide an overview of the current knowledge of compounds -- based on preclinical an d clinical work - which are potentially interesting to target emotional memory processing in PTSD. We will discuss applied dosages, population, timing of treatment and exposure. Second, we will use this knowledge to define pertinent questions for future and novel developments to target PTSD. We identified the following potential compounds: Propranolol, Cortisol, D-Cycloserin, Ketamine, Oxytocine and MDMA (XTC).

**Conclusions**: We conclude that reconsolidation presents an interesting opportunity to modify or alter fear and fear-related memories. Several compounds are being used off label in augmentation of psychotherapy for PTSD. Following a roadmap will assist in moving the field forward in terms of design, dosage as well as effectivity as augmentation strategies for treatment of PTSD.
